Table 2 ED visits where a MSUD was prescribed at discharge from 2019 to 2021
Data Subset | Naloxone | Buprenorphine | Naltrexone | Methadone | Acamprosate | Disulfiram |
|---|---|---|---|---|---|---|
Percentage (counts) | Percentage (counts) | Percentage (counts) | Percentage (counts) | Percentage (counts) | Percentage (counts) | |
All ED visitsa | 1.3 (138/10510) | 0.3 (33/10510) | 0.6 (58/10510) | 0.2 (19/10510) | 0.1 (12/10510) | 0.1 (9/10510) |
UDS fentanyl POS | 3.5 (49/1408) | 1.5 (21/1408) | 0.2 (3/1408) | 0.2 (3/1408) | 0.1 (1/1408) | 0.1 (1/1408) |
Current diagnosis of OUD | 7.0 (72/1028) | 2.6 (27/1028) | 0.3 (3/1028) | 0.9 (9/1028) | 0.0 (0/1028) | 0.1 (1/1028) |
Current OUD diagnosis and UDS fentanyl POS | 8.7 (30/346) | 6.1 (21/346) | 0.9 (3/346) | 0.3 (1/346) | 0.0 (0/346) | 0.3 (1/346) |
UDS fentanyl POS without an OUD diagnosis | 1.8 (19/1062) | 0.0 (0/1062) | 0.0 (0/1062) | 0.2 (2/1062) | 0.1 (1/1062) | 0.0 (0/1062) |
Discharge diagnosis SUD-related | 3.7 (108/2953) | 0.5 (15/2953) | 1.4 (42/2953) | 0.1 (2/2953) | 0.3 (8/2953) | 0.2 (7/2953) |
Discharge diagnosis OUD-related | 16.3 (50/307) | 2.6 (8/307) | 0.3 (1/307) | 0.3 (1/307) | 0.0 (0/307) | 0.0 (0/307) |
Discharge diagnosis SUD-related and UDS fentanyl POS | 9.1 (37/405) | 2.0 (8/405) | 0.5 (2/405) | 0.2 (1/405) | 0.0 (0/405) | 0.2 (1/405) |
Discharge diagnosis SUD-related excluding OUD and AUD | 4.9 (51/1038) | 0.3 (3/1038) | 0.3 (1038) | 0.0 (0/1038) | 0.0 (0/1038) | 0.0 (0/1038) |
Discharge diagnosis SUD-related excluding OUD and AUD but with a UDS fentanyl POS | 8.4 (19/225) | 0.0 (0/225) | 0.9 (2/225) | 0.0 (0/225) | 0.0 (0/225) | 0.0 (0/225) |